What is the total value of India's pharmaceutical export to Taiwan?

India exported pharmaceuticals worth $5.2M to Taiwan across 211 verified shipments.

Who are the top Indian pharmaceutical exporters to Taiwan?

1. M S TAIWAN BLOOD SERVICES FOUNDATION — $1.0M. 2. SCINOPHARM TAIWAN LTD — $162.4K. 3. M/S. TAIWAN BLOOD SERVICES, FOUNDATION — $150.9K. Total: 44 suppliers.

Which companies in Taiwan import pharmaceuticals from India?

1. RELIANCE LIFE SCIENCES PRIVATE LIMITED — $4.7M. 2. TEYRO LABS PRIVATE LIMITED — $162.4K. 3. EUGIA PHARMA SPECIALITIES LIMITED — $143.0K. 38 buyers total.

What pharmaceutical products does India export most to Taiwan?

1. Plasma ($4.7M, 90.3%); 2. Paclitaxel ($162.4K, 3.1%); 3. Amphotericin ($143.0K, 2.7%); 4. Everolimus ($139.0K, 2.7%); 5. Tacrolimus ($32.5K, 0.6%)

Why does Taiwan import pharmaceuticals from India?

India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $5.2M corridor reflects quality compliance and pricing advantages.

What certifications do Indian pharmaceutical exporters need to supply Taiwan?

WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.

What is the average shipment value for India to Taiwan pharmaceutical trade?

$24.8K per consignment across 211 shipments.

How many Indian pharmaceutical companies export to Taiwan?

44 Indian companies. Largest: M S TAIWAN BLOOD SERVICES FOUNDATION with $1.0M.

How can I find verified Indian pharmaceutical suppliers for Taiwan?

TransData Nexus covers 44 active exporters with shipment history and trade values at transdatanexus.com.

Taiwan to India Pharmaceutical Import (2026) — $5.2M, 44 Foreign Suppliers | TransData Nexus

Taiwan to India Pharmaceutical Import (2026) — $5.2M, 44 Foreign Suppliers | TransData Nexus | TransData Nexus

Top Pharmaceutical Formulations — Taiwan to India

#	Formulation	Value	Share
1	Plasma	$4.7M	90.3%
2	Paclitaxel	$162.4K	3.1%
3	Amphotericin	$143.0K	2.7%
4	Everolimus	$139.0K	2.7%
5	Tacrolimus	$32.5K	0.6%
6	Protein	$17.9K	0.3%
7	Sodium	$3.4K	0.1%
8	Rituximab	$2.2K	0.0%
9	Collagen	$1.1K	0.0%
10	Atorvastatin	$1.0K	0.0%
11	Ezetimibe	$1.0K	0.0%
12	Serum	$853	0.0%
13	Budesonide	$774	0.0%
14	Biotin	$698	0.0%
15	Metformin	$476	0.0%

India imports 20+ pharmaceutical formulations from Taiwan with a combined trade value of $5.2M. Key products include Plasma ($4.7M), Paclitaxel ($162K), Amphotericin ($143K), Everolimus ($139K), Tacrolimus ($32K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 211 verified Indian Customs (DGFT) shipment records.

Top Pharmaceutical Products — Taiwan to India Trade Routes

1Plasma$4.7M

2Paclitaxel$162K

3Amphotericin$143K

4Everolimus$139K

5Tacrolimus$32K

6Protein

Top Taiwan Suppliers to India

1M S Taiwan Blood Services Foundation

$1.0M

2Scinopharm Taiwan Ltd

$162K

3M/s. Taiwan Blood Services, Foundation

$151K

4Tty Biopharm Company Limited

$143K

5Chunghwa Chemical Synthesis & Biotech Co., Ltd.

$129K

Trade Statistics

Total Value$5.2M

Shipments211

Indian Exporters44

Taiwan Buyers38

Avg Shipment$25K

Products42

Other Import Origins

United States$2.7B Germany$929.2M China$767.5M Italy

Last updated: March 28, 2026

India–Taiwan Pharmaceutical Trade Corridor Analysis

Historical evolution, India's market position, and recent developments

1Trade Corridor Evolution

The pharmaceutical trade corridor between Taiwan and India has experienced notable growth from 2022 to 2026. In 2022, the total import value was approximately $1.2 million USD, with 50 shipments from 10 Taiwanese suppliers to 15 Indian buyers. By 2026, these figures had increased to a total import value of $5.2 million USD, encompassing 211 shipments from 44 Taiwanese suppliers to 38 Indian buyers. This growth underscores the strengthening bilateral trade relations and the expanding role of Taiwanese pharmaceutical products in the Indian market.

2Taiwan's Role in India's Pharma Imports

Taiwan's contribution to India's pharmaceutical imports remains modest but significant. In 2026, Taiwan accounted for approximately 0.2% of India's total pharmaceutical imports, valued at $2.8 billion USD. The primary categories imported from Taiwan include plasma products, anticancer agents like paclitaxel and everolimus, and immunosuppressants such as tacrolimus. These products are crucial for treating various medical conditions, indicating Taiwan's specialized role in supplying niche pharmaceutical formulations to India.

3Recent Developments

Taiwan Regulatory Landscape for Indian Pharmaceutical Exports

Registration process, GMP requirements, import documentation

1CDSCO Registration Process

Taiwanese pharmaceutical companies seeking to import products into India must navigate the CDSCO registration process. This involves submitting an application through the CDSCO's online portal, providing detailed product information, manufacturing licenses, and quality control certificates. The process includes a technical evaluation, which may involve site inspections and assessments of clinical data. While clinical trial data may be waived for certain products, the overall timeline for registration can range from several months to over a year, depending on the product's complexity and the completeness of the submitted documentation.

2GMP & Manufacturing Standards

India requires that foreign manufacturing sites adhere to Good Manufacturing Practice (GMP) standards as outlined by the World Health Organization (WHO). Taiwanese manufacturers must obtain WHO-GMP certification to demonstrate compliance with these standards. The CDSCO conducts inspections to verify adherence to GMP guidelines, ensuring that imported pharmaceutical products meet India's safety and quality requirements.

3Import Documentation

Importing pharmaceutical products into India necessitates several key documents:

Import License (Form 10): Issued by the CDSCO, this license authorizes the importation of specific pharmaceutical products.

Registration Certificate: Confirms that the product has been approved for sale in India.

No Objection Certificate (NOC): Required for certain products, indicating no objection from the relevant authorities.

Test License: Permits the importation of drugs for testing, analysis, or clinical trial purposes.

Customs Documentation: Includes commercial invoices, packing lists, and bills of lading, essential for customs clearance.

Ensuring all documentation is accurate and complete is crucial for a smooth import process.

IMPORT_TRENDS

TransData Nexus Research · Taiwan regulatory databasesMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Data Source: Indian Customs (DGFT) export shipping bill records covering all pharmaceutical shipments from India.
2.Country Matching: Shipments to Taiwan identified using destination country codes from customs declarations.
3.Statistical Normalization: Values are statistically normalized to remove outlier transactions and ensure accurate market share representation.
4.Coverage: 211 verified shipments from 44 Indian exporters to 38 Taiwan buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

44 Exporters

38 buyers tracked

Expert-Reviewed

By pharmaceutical trade specialists

Taiwan to India Pharmaceutical Import

Top Pharmaceutical Formulations — Taiwan to India

Top Pharmaceutical Products — Taiwan to India Trade Routes

Top Taiwan Suppliers to India

Trade Statistics

Other Import Origins

India–Taiwan Pharmaceutical Trade Corridor Analysis

1Trade Corridor Evolution

2Taiwan's Role in India's Pharma Imports

3Recent Developments

Top Indian Buyers from Taiwan

Product Routes

Full Dataset Access

Taiwan Regulatory Landscape for Indian Pharmaceutical Exports

1CDSCO Registration Process

2GMP & Manufacturing Standards

3Import Documentation

Product Categories & Therapeutic Trends — India to Taiwan

1Dominant Import Categories

2Innovation & Specialty Imports

3Import Demand Drivers

Trade Policy & Tariff Intelligence — India and Taiwan

1India's Import Tariff Structure

2Trade Agreements & Preferences

3IP, Patents & Price Control

Supply Chain & Logistics — India to Taiwan Pharma Shipments

1Shipping Routes & Transit

2Port Infrastructure

3Indian Customs & Cold Chain

Market Opportunity Assessment — Taiwan for Indian Pharma

1India's Import Dependency

2Taiwan Companies in India

3Outlook & Self-Reliance

FAQ — India to Taiwan Pharmaceutical Trade